outcomes is currently unknown. Here, we investigated whether the proportion of the ductal component predicts oncologic outcomes in ductal adenocarcinoma.
INTRODUCTION AND OBJECTIVES:
To evaluate the diagnostic accuracies of FDG PET/CT and morphological imaging (CT and MRI) in recurrent urothelial cancer (UC) after primary treatment.
METHODS: Data of patients with recurrent UC after primary treatment were collected in a retrospective multicenter (San Raffaele Hospital, Milan; IOVeIRCCS, Padua; Hospital of Ferrara, Ferrara; Mayo Clinic, Rochester; University of Bologna) study. Inclusion criteria were: 1) patients with a known history of UC in the bladder and/or in the upper urinary tract (UTUC); 2) FDG PET/CT images after curative treatment of the primary tumor; 3) morphological imaging modalities (CT and MRI) performed before at least 3 months from PET/CT and 4) available standard of reference (e.g. histological data or imaging modalities) for the assessment of PET/CT findings. Exclusion criteria were other abdominal tumours and chemotherapy administration concomitant to imaging and non-urothelial cancer variants. Sensitivities, specificities, positive and negative predictive values were evaluated for all patients and separately for bladder and UTUC. RESULTS: Overall, 287 patients were included in the study. Two-hundred thirteen patients underwent cystectomy (74.2%), 35 nephoureterectomy (12.2%), 32 both cystectomy and nephoureterectomy (11.1%) and 7 other type of treatment for UTUC (endo-urology or segmental ureterectomy). Neoadjuvant and adjuvant treatments were performed in 36 (12,5%) and 111 (38,7%) patients, respectively. Sensitivity and specificity of PET/CT for the detection of recurrent UC were 94% (91%-96%) and 79% (68%-88%), respectively (Table 1) . However, sensitivity was higher for bladder than UTUC cancer (95% vs. 85%) while specificity was lower in bladder cancer (78% vs. 85% for bladder and UTUC, respectively). The distribution of pathological FDG uptake was: 58 at local site, 126 at lymph nodes, 58 at skeletal site, 53 at lung, 28 at liver and 26 in other sites. PET/CT and morphological imaging modalities findings were available in 198 patients. The results were positively concordant in 137 patients, negatively concordant in 23 patients and discordant in 38 patients (20 negative at ceCT/MRI vs positive at PET/CT and 18 positive at ceCT/MRI and negative at PET/ CT) (K Cohen¼ 0.426; p<0.001). Sensitivities, specificities and accuracies of FDG PET/CT and morphological imaging for the detection of recurrent bladder and UTUC cancer were 94% (90%-97%) vs. 86% (81%-92%), 79% (67%-92%) vs. 59% (44%-74%) and 91% (87%-95%) vs. 81% (75%-86%), respectively. CONCLUSIONS: FDG PET/CT has a high diagnostic accuracy for the identification of recurrent UC, particularly in patients with bladder cancer. Moreover, its performance seems higher than conventional imaging for both bladder and UTUC cancer.
INTRODUCTION AND OBJECTIVES: Non-contrast CT imaging may be helpful in distinguishing cystic from solid lesions with a proposed cutoff of <20 HU. Current guidelines suggest that renal lesions <20HU on pre-contrast study require no further evaluation as they are most commonly benign cysts. We evaluated the frequency of pRCC presenting with low pre-contrast attenuation that might otherwise be considered radiographically benign, as well as the relationship of this metric to histologic subtype of pathologically proven pRCC.
METHODS: The prospectively maintained Fox Chase Cancer Center kidney cancer database was reviewed for pT1 or T2 pRCC between 2003-2015. Patients were categorized by papillary subtype. Preoperative non-contrast CT images were analyzed. Maximum tumor diameter was measured in centimeters. Attenuation was calculated as the average Hounsfield Units (HU) from 6 distinct axial regions. Low attenuation was defined as ¼ 20 HU and high attenuation as >20 HU. We assessed the relationship between pre-operative renal mass attenuation and pRCC subtype using logistic regression controlling for stage, age, gender and laterality.
RESULTS: 58 patients were identified with pT1 or pT2 pRCC in whom preoperative non-contrast CT images were evaluable. 24 (41%) had type 1 and 34 (59%) had type 2 pRCC. No significant differences were noted in age (median 66.75 vs. 63.41 years, p ¼ 0.23) or tumor diameter (median 5.27 vs. 6.32 cm, p ¼ 0.18). 27 patients (47%) exhibited an average preoperative non-contrast ROI ¼ 20 HU, of which 6 patients (22%) were type 1 pRCC and 21 patients (78%) were type 2 pRCC. Type 1 pRCC demonstrated a higher attenuation than type 2 tumors using both average and max attenuation (29.6 vs. 20.6 HU, p <0.01; and 37.3 vs 26.3 HU, p ¼ <0.01, respectively). After adjustment, HU was an independent predictor of pRCC subtype. Relative to lowdensity tumors, high-density tumors were 80% less likely to be type 2 pRCC (OR ¼ 0.20, 95% CI 0.06-0.70, p¼0.01).
CONCLUSIONS: Nearly half of our evaluated pRCC presented with low attenuation lesions (<20HU) on unenhanced CT and would have been dismissed as benign lesions under current guidelines. Importantly, we demonstrate that not only were these low attenuation lesions not benign, but they were associated with the more aggressive type 2 subtype. These data contradict the opinion that low attenuation renal lesions require no further evaluation, and suggest that attenuation on non-contrast CT imaging is insufficient as a single parameter to rule out malignancy.
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PD11-03 IMPACT OF MAGNETIC RESONANCE SPECTROSCOPIC IMAGING ON DIFFERENTIAL DIAGNOSIS OF RENAL TUMORS
Masahiro Sumura*, Haruki Ajiki, Chiaki Koike, Keita Inoue, Keisuke Nakanishi, Hiroaki Yasumoto, Tsuyoshi Yoshizako, Hajime Kitagaki, Hiroaki Shiina, Izumo, Shimane, Japan INTRODUCTION AND OBJECTIVES: The utility of magnetic resonance imaging (MRI) for diagnosis of a renal tumor is controversial. MR spectroscopy (MRS), a noninvasive method utilized for assessment of biochemical tissue characteristics in vivo, has value for differentiation of tumors in the brain, breast, and prostate. However, there are few reports of MRS examinations of kidneys. Here, we evaluated the diagnostic potential of MRS for renal tumors.
METHODS: We analyzed 45 renal tumors in 45 patients (age 60-82 years, median 62 years; clinical stage: T1a, n¼25; T1b, n¼9; T2a, n¼1; T2b, n¼1; T3a, n¼6; T4, n¼1). All patients underwent preoperative MRS examinations with a 1.5 T MR device equipped with a phased array type external surface coil, in which respiratory-triggered single voxel MRS was performed with a point-resolved spectroscopy sequence (TR, 2000 ms; TE, 135 ms). The obtained spectra were analyzed for choline resonances at 3.2 ppm, after normalization for noise outside the diagnostic range. Choline/noise ratio (CNR) values were automatically calculated using the "R" software package, then the CNRs in spectra obtained from both cancerous and benign tumors were compared. Histological results were defined as the standard for reference.
RESULTS: Of the 45 tumors examined, 41 including 3 cystic tumors were malignant in histological findings, while 2 were histologically diagnosed as angiomyolipoma (AML), 1 as oncocytoma and 1 as tuberculous granuloma (TG). In all cases, the obtained spectra were of sufficient quality for diagnosis. The mean choline CNR value for malignant lesions was 3.4, while that was 1.01 for AML, 1.05 for oncocytoma, and 1.12 for TG. Malignant renal tumors tended to show higher CNR values than benign tumors as well as in tumors with higher grade.
CONCLUSIONS: Although further studies are necessary, our findings indicate that MRS has potential to differentiate malignant from benign renal tumors. Furthermore, it may be an effective diagnostic tool for cystic renal tumor cases.
